CA2377228A1 - Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective - Google Patents

Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective Download PDF

Info

Publication number
CA2377228A1
CA2377228A1 CA002377228A CA2377228A CA2377228A1 CA 2377228 A1 CA2377228 A1 CA 2377228A1 CA 002377228 A CA002377228 A CA 002377228A CA 2377228 A CA2377228 A CA 2377228A CA 2377228 A1 CA2377228 A1 CA 2377228A1
Authority
CA
Canada
Prior art keywords
cell
e4orf4
compound
pp2a
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002377228A
Other languages
English (en)
Inventor
Philip E. Branton
Richard C. Marcellus
Gordon C. Shore
Diana E. Roopchand
Joseph M. Lee
S. Serge Shahinian
A. Howard Bussey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2377228A1 publication Critical patent/CA2377228A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne l'aptitude de la protéine adénovirale E4orf4 à provoquer la mort de cellules néoplasiques, mais pas de cellules non néoplasiques. Cette découverte ouvre la voie à la mise au point de réactifs et de composés thérapeutiques anti-néoplasiques. De plus, l'invention concerne des méthodes de criblages d'analogues E4orf4 présentant des propriétés anti-néoplasiques.
CA002377228A 1999-07-12 2000-07-11 Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective Abandoned CA2377228A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35160299A 1999-07-12 1999-07-12
US09/351,602 1999-07-12
PCT/CA2000/000817 WO2001004629A1 (fr) 1999-07-12 2000-07-11 Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective

Publications (1)

Publication Number Publication Date
CA2377228A1 true CA2377228A1 (fr) 2001-01-18

Family

ID=23381575

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002377228A Abandoned CA2377228A1 (fr) 1999-07-12 2000-07-11 Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective

Country Status (4)

Country Link
EP (1) EP1196773A1 (fr)
AU (1) AU5959200A (fr)
CA (1) CA2377228A1 (fr)
WO (1) WO2001004629A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827866B1 (fr) 2001-07-27 2004-12-10 Pasteur Institut Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
CA2408207A1 (fr) 2002-10-16 2004-04-16 Institut Pasteur Peptides liant la proteine phosphatase 2a et polynucleotides les codant
CN119780400B (zh) * 2024-12-25 2026-04-14 华硼中子科技(杭州)有限公司 细胞辐射敏感性确定方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695944A (en) * 1995-05-05 1997-12-09 Thomas Jefferson University Modulation of bcl-2 phosphorylation
WO1997037037A1 (fr) * 1996-03-29 1997-10-09 Novartis Ag Modulateur de la phosphatase
DE69725882T2 (de) * 1996-07-05 2004-07-29 Branton, Philip E., St. Lambert Adenovirus e4 proteine für induktion von zelltod
EP0874052A3 (fr) * 1997-04-22 1999-02-24 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Acide nucléique codant pour une phosphatase de protéine humaine

Also Published As

Publication number Publication date
AU5959200A (en) 2001-01-30
WO2001004629A1 (fr) 2001-01-18
EP1196773A1 (fr) 2002-04-17
WO2001004629A9 (fr) 2002-08-29

Similar Documents

Publication Publication Date Title
Cheng et al. Peptide antibodies to the human c‐fyn gene product demonstrate pp59c‐fyn is capable of complex formation with the middle‐T antigen of polyomavirus.
Cordle et al. Lipopolysaccharide induces phosphorylation of MAD3 and activation of c-Rel and related NF-kappa B proteins in human monocytic THP-1 cells
Yang et al. DNA Damage–Induced Protein 14-3-3 σ Inhibits Protein Kinase B/Akt Activation and Suppresses Akt-Activated Cancer
Benkirane et al. Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA‐dependent protein kinase PKR
Zhang et al. Role of Toll-like receptor signaling in the apoptotic response of macrophages to Yersinia infection
Taylor et al. Mechanisms of G2 arrest in response to overexpression of p53
Guerra et al. Vaccinia virus E3 protein prevents the antiviral action of ISG15
AU2008316577B2 (en) Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
Zhao et al. Myeloid neddylation targets IRF7 and promotes host innate immunity against RNA viruses
JP4418103B2 (ja) 新規なヒトチェックポイントキナーゼ、ｈＣＤＳ１、組成物および方法
Duerksen-Hughes et al. HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblast LM cells
Park et al. NLRP3 inflammasome activation enhanced by TRIM25 is targeted by the NS1 protein of 2009 pandemic influenza a virus
JP2008505307A (ja) ＨＡＵＳＰ−Ｍｄｍ２相互作用及びその使用
EP0889971B1 (fr) Modulateur de la phosphatase
WO2000036111A1 (fr) Utilisations therapeutique et diagnostique de la proteine tyrosine phosphatase tc-ptp
US6235467B1 (en) Methods for identifying cell cycle regulators
CA2377228A1 (fr) Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective
WO2019024518A1 (fr) Médicament pour le traitement d'une maladie impliquant la protéine chimioattractive des monocytes de type 1 (mcp-1) par ajustement de la phosphorylation de yb-1
US20100310508A1 (en) METHODS OF TREATMENT INVOLVING p21/CIP1
WO2001004296A1 (fr) Polypeptides rbp1 et leurs utilisations
Meyers et al. Crosstalk between epidermal growth factor receptor and P-glycoprotein in actinomycin D-resistant Chinese hamster lung cells
US6960430B2 (en) Screening methods for compounds useful in the regulation of cell proliferation
US20040048821A1 (en) Enhancement of drug cytotoxicity in tumor cells containing mutant Rb gene
Crinelli et al. Activation of the ubiquitin proteolytic system in murine acquired immunodeficiency syndrome affects IκBα turnover
CN121987790A (zh) 靶向abhd6介导的耐药通路的肝细胞癌耐药逆转产品及应用

Legal Events

Date Code Title Description
FZDE Dead